Journal of Pediatric Gastroenterology & Nutrition:
Measurement of Mucosal Conductivity by MII Is a Potential Marker of Mucosal Integrity Restored in Infants on Acid-suppression Therapy
Loots, Clara M*; Van Wijk, Michiel P*; Smits, Marije J*; Wenzl, Tobias G†; Benninga, Marc A*; Omari, Taher I‡
*Department of Pediatric Gastroenterology and Nutrition, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands
†Klinik für Kinder- und Jugendmedizin, Universitätsklinikum der RWTH, Aachen, Germany
‡University of Adelaide, Adelaide, Australia.
Received 17 October, 2010
Accepted 16 January, 2011
Address correspondence and reprint requests to C.M. Loots (e-mail: firstname.lastname@example.org).
The authors report no conflicts of interest.
Esophageal multichannel intraluminal impedance (MII) allows measurement of the conductivity of adjacent contents. During esophageal rest, raw impedance levels may represent mucosal integrity. We assessed the influence of proton pump inhibitors (PPIs) on presumed mucosal integrity by reanalyzing raw MII levels of 21 pH-MII tracings from infants with gastroesophageal reflux (GER) disease before and after esomeprazole treatment. Median (interquartile range) esophageal MII increased during treatment, 938 (652–1304) versus 1885 (1360–2183) Ohm, P < 0.0001. Patients with lower MII levels demonstrated a larger increase on therapy: Spearman r2 = 0.28, P = 0.014. No correlation with standard GER parameters was observed. In conclusion, PPI therapy increases MII levels in infants with symptomatic GER disease.
Esophageal multichannel intraluminal impedance (MII) is a technique that uses impedance to indirectly measure the conductivity of the esophageal lumen between multiple electrodes on a catheter (1), and has been used for the detection of gastroesophageal reflux (GER) episodes in adults and in children (2–7). Esophageal boluses with high ionic content, such as saliva or gastric fluids, cause a drop in impedance in all subjects, whereas a less conductive bolus, such as air, causes an increase in impedance signal.
During rest, the esophagus is collapsed and the level of impedance measured represents the inverse conductivity of the esophageal mucosa. The level of raw impedance shows high variability between subjects and low overall impedance levels appear to be a characteristic feature of patients with GER disease (GERD) (8). Farré et al (9) have recently reported that exposure of the esophageal lumen to acid solutions, both in vitro and in vivo, causes a temporary drop in impedance level measured at times when no reflux or swallow was noted. This was attributed to an increased conductivity of the esophageal mucosa related to an increase in transcellular ionic transport caused by dilated intracellular spaces (DIS). These data suggest that low impedance levels do indeed reflect the integrity of the esophageal mucosa and have the potential for being a marker of the existence of mucosal damage.
This new diagnostic paradigm may have potential in infants, who are difficult to endoscope safely and therefore are frequently prescribed proton pump inhibitors (PPI) without proof of mucosal changes. Furthermore, diagnosing GERD in infants is challenging because typical GER symptoms such as crying, irritability, and vomiting are not exclusive to and correlate poorly with GERD. The integrity of the esophageal mucosa reflected by the measurement of raw impedance levels may guide use of acid-suppression therapies. Although proven effective for healing acid-related inflammatory changes in adult GERD (10–12) and for reducing acid exposure in infants (13–15), PPIs do not improve symptoms in infants treated empirically (16). In addition, we have previously shown that PPI (esomeprazole) therapy does not alter the frequency of impedance-detected bolus reflux episodes (liquid, mixed, and gas) in infants with typical reflux symptoms (17). A better way is clearly needed to diagnose GERD in infants and to target PPI therapy to the few infants who may benefit from this therapy. To date, it is unknown whether PPI therapy changes raw impedance in infants, children, and adults with pathologic GER disease. The hypothesis of this study was that PPI therapy would increase raw impedance values in infants with symptoms of GERD and evidence of increased esophageal acid exposure.
The study cohort comprised preterm and term infants. Results on PPI effectiveness on frequency of impedance-detected bolus reflux episodes, acid exposure, study procedures, and symptom recording were published previously in detail (18). Informed consent for the initial study was obtained in all of the children, and the study protocol was approved by the human research ethics and drug therapeutics committees of the Women's and Children's Hospital, North Adelaide (South Australia). These tracings were reanalyzed retrospectively for the purpose of this study. An abridged description follows.
All of the infants were referred for 24-hour pH-impedance monitoring because of symptoms suggestive of GERD such as vomiting, coughing, feed refusal, irritability, crying, back arching, failure to thrive, apnea, and failure to respond to a trial of nonpharmacological therapy. Infants with a baseline acid exposure showing a pH < 4 for more than 5% of the study period received oral esomeprazole, 0.5 mg/kg for 7 days once daily in the morning, 30 minutes before feeding. A pH-MII study was repeated on therapy. Symptom episodes of vomiting, apnea, choking, irritability/fussing/crying, back arching, facial grimacing, and gagging were scored during both 24-hour studies by staff responsible for the routine care of the infant or the infant's parents.
Twenty hours of raw MII values for the most distal MII segment were exported from each recording in text format at 1 sample per 10 seconds (Sandhill Scientific, Highlands Ranch, CO) yielding 7181 (range 6131–7197) data points. To remove the potential confounding effects of gas reflux the raw dataset was further filtered to remove all data points >5000 Ohm [the standard cutoff for definition of the presence of gas in the esophagus (19)]. The median impedance value for all of the remaining data points was then calculated. The objectively derived impedance level was compared for each infant before and during therapy. All of the other reflux and symptom data were taken from our existing records unmodified, and no reanalysis of any of these data was performed.
The impedance data were not normally distributed and are shown as medians (interquartile range). Comparisons were made using Wilcoxon signed-rank test and Spearman correlation statistics. Statistical significance is defined as P < 0.05.
Twenty-one preterm and term infants (mean age 7.4 ± 4.2 weeks, all <1 month term corrected age) were included for analysis. Median weight at baseline was 2930 g (range 1910–4145 g).
Standard Reflux Parameters Before and During PPI Therapy
Traditional pH-MII reflux variables of acid exposure in the distal esophagus (reflux index, % of time pH < 4), number of GER events, GER events lasting >5 minutes, and quality of GER as well as the number of symptoms recorded during the 24-hour pH-MII study pre- and posttreatment are presented in Table 1.
Impedance Level Before and During PPI Therapy
The median (interquartile range) esophageal impedance level increased significantly during PPI treatment, 938 (652–1304) Ohm pretreatment versus 1885 (1360–2183) Ohm on treatment, P < 0.0001. Data per individual patient before and during treatment are shown in Figure 1A. At baseline, most infants had impedance levels in the range of 0 to 1500 Ohm, but there appeared to be a bimodal distribution of impedance levels, with a second cluster of 4 infants with impedance levels of >2000 Ohm (Fig. 1A). This contrasts with the impedance levels on therapy of 1000 to 3000 Ohm with no apparent bimodal distribution (Fig. 1B). The 4 infants with high impedance levels at baseline did not increase impedance level further on therapy (2469 [2168–2729] vs 2630 [2252–2915]) Ohm, P = 0.5), whereas the remaining infants with impedance levels <1500 Ohm did (850 [590–1101] vs 1831 [1326–2008] Ohm, P = 0.0001). Furthermore, we observed a significant correlation between the baseline impedance level and the change in impedance during PPI treatment; patients with lower impedance levels demonstrated a larger increase on therapy: Spearman r2 = 0.28, P = 0.014 (Fig. 1C).
Although both impedance and acid exposure were significantly changed by PPI therapy overall, on a patient-by-patient basis the level of impedance did not correlate with the reflux index (Spearman r2 = 0.09, P = 0.21). Neither did the change in impedance correlate with the change in reflux index (Spearman r2 = 0.11, P = 0.17). Correlations of impedance level with other reflux variables were also insignificant.
In this study we have shown that esophageal impedance levels increase in infants in response to PPI treatment. This increase is larger in patients with lower initial impedance levels. There was no correlation between the impedance level and conventional parameters of esophageal acid exposure and reflux, suggesting that this effect relates to factors beyond the simple reduction of esophageal exposure to H+ ions containing fluids.
We were unable to assess the presence of esophageal mucosal damage in the patients studied because endoscopic investigations in this age group are only considered in therapy-resistant patients and there are no noninvasive markers for this. Based on adult studies that clearly link impedance levels to mucosal integrity, our findings, however, do show that some infants have low impedance levels that are suggestive of altered mucosal integrity. With erosive esophagitis being uncommon in infants undergoing endoscopy (20,21), the low impedance levels may reflect more subtle changes in mucosal integrity, as is the case with patients with nonerosive reflux disease who have high levels of esophageal acid exposure but no esophagitis.
One postulated mechanism leading to higher mucosal conductance is the presence of DIS. DIS reduce transepithelial resistance by increasing transcellular ionic transport (22,23). In patients with erosive and nonerosive GER disease, DIS are present (23), and the extent of DIS is reduced by PPI therapy in these patients (24). The presence of DIS may explain the low impedance levels recorded in our population when studied off PPI therapy. It could also explain the correlation between the low impedance level before treatment and the change in impedance during PPI treatment. On the contrary, a recent study showed that weakly acidic solutions can cause DIS similar to acidic solutions, albeit in healthy adults in a highly experimental setting (25). Further studies are needed to elucidate the exact relation between DIS and baseline impedance levels. The fact that the impedance levels change so dramatically after only a relatively short period of time (7 days) also suggests that the mechanisms involved are subtle. Although healing of esophagitis may take weeks or months, this presumed presence of DIS is readily and quickly reversed in response to reducing the duration of time that the esophageal mucosa is exposed to acid.
In conclusion, we have demonstrated that PPI therapy increases impedance levels measured by MII in preterm and term infants with symptomatic GER disease. The true meaning of low impedance (high esophageal mucosal conductance) for research and clinical purposes needs to be determined. Our observations may be explained by acid suppression's restoring the DIS and therefore mucosal integrity of the esophagus. Furthermore, this incidental finding does suggest that the level of impedance during a 24-hour period may be a parameter worthy of further investigation in terms of potential clinical relevance, particularly in infants in whom endoscopy is usually inappropriate.
1. Silny J. Intraluminal multiple electric impedance procedure for measurement of gastrointestinal motility. J Gastrointest Motil 1991; 3:151–162.
2. Del Buono R, Wenzl TG, Rawat D, et al. Acid and nonacid gastro-oesophageal reflux in neurologically impaired children: investigation with the multiple intraluminal impedance procedure. J Pediatr Gastroenterol Nutr 2006; 43:331–335.
3. Loots CM, Benninga MA, Davidson GP, et al. Addition of pH-impedance monitoring to standard pH monitoring increases the yield of symptom association analysis in infants and children with gastroesophageal reflux. J Pediatr 2009; 154:248–252.
4. Rosen R, Lord C, Nurko S. The sensitivity of multichannel intraluminal impedance and the pH probe in the evaluation of gastroesophageal reflux in children. Clin Gastroenterol Hepatol 2006; 4:167–172.
5. Rosen R, Nurko S. The importance of multichannel intraluminal impedance in the evaluation of children with persistent respiratory symptoms. Am J Gastroenterol 2004; 99:2452–2458.
6. van Wijk MP, Benninga MA, Omari TI. Role of the multichannel intraluminal impedance technique in infants and children. J Pediatr Gastroenterol Nutr 2009; 48:2–12.
7. Wenzl TG. Evaluation of gastroesophageal reflux events in children using multichannel intraluminal electrical impedance. Am J Med 2003; 115(suppl 3A):161S–165S.
8. Wasko-Czopnik D, Blonski W, Paradowski L. Diagnostic difficulties during combined multichannel intraluminal impedance and pH monitoring in patients with esophagitis or Barrett's esophagus. Adv Med Sci 2007; 52:196–198.
9. Farré R, Blondeau K, Clement D, et al. Evaluation of esophageal mucosa integrity “in vivo.” Validation of basal intraluminal impedance measurements to assess non-erosive changes induced by esophageal acid exposure in rabbit and healthy human subjects. Gastroenterology 2010; 138:S555.
10. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798–1810.
11. Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; 2:CD003244.
12. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. Pharmacol Res 2009; 59:135–153.
13. Moore DJ, Tao BS, Lines DR, et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003; 143:219–223.
14. Tighe MP, Afzal NA, Bevan A, et al. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Paediatr Drugs 2009; 11:185–202.
15. Tolia V, Bishop PR, Tsou VM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2006; 42:384–391.
16. Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009; 154:514–520.
17. Omari TI, Miki K, Fraser R, et al. Esophageal body and lower esophageal sphincter function in healthy premature infants. Gastroenterology 1995; 109:1757–1764.
18. Omari TI, Lundborg P, Sandstrom M, et al. Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. J Pediatr 2009; 155:222–228.
19. van Wijk MP, Sifrim D, Rommel N, et al. Characterisation of intraluminal impedance patterns associated with gas reflux (belching) in healthy volunteers. Gastroenterology 2006; 130:A116.
20. Campanozzi A, Boccia G, Pensabene L, et al. Prevalence and natural history of gastroesophageal reflux: pediatric prospective survey. Pediatrics 2009; 123:779–783.
21. Gilger MA, El-Serag HB, Gold BD, et al. Prevalence of endoscopic findings of erosive esophagitis in children: a population-based study. J Pediatr Gastroenterol Nutr 2010; 47:141–146.
22. Van Malenstein H, Farre? R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2008; 103:1021–1028.
23. Edebo A, Vieth M, Tam W, et al. Circumferential and axial distribution of esophageal mucosal damage in reflux disease. Dis Esophagus 2007; 20:232–238.
24. Calabrese C, Bortolotti M, Fabbri A, et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol 2005; 100:537–542.
25. Farre R, Fornari F, Blondeau K, et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut 2010; 59:164–169.
children; dilated intracellular spaces; infants; proton pump inhibitor; reflux; reflux disease treatment; impedance; esomeprazole; mucosal integrity; pH impedance
Copyright 2011 by ESPGHAN and NASPGHAN